186 related articles for article (PubMed ID: 37564202)
1. A novel mouse model of heart failure with preserved ejection fraction after chronic kidney disease induced by retinol through JAK/STAT pathway.
Liu B; Shalamu A; Pei Z; Liu L; Wei Z; Qu Y; Song S; Luo W; Dong Z; Weng X; Ge J
Int J Biol Sci; 2023; 19(12):3661-3677. PubMed ID: 37564202
[TBL] [Abstract][Full Text] [Related]
2. Telmisartan ameliorates cardiac fibrosis and diastolic function in cardiorenal heart failure with preserved ejection fraction.
Chang D; Xu TT; Zhang SJ; Cai Y; Min SD; Zhao Z; Lu CQ; Wang YC; Ju S
Exp Biol Med (Maywood); 2021 Dec; 246(23):2511-2521. PubMed ID: 34342551
[TBL] [Abstract][Full Text] [Related]
3. Growth hormone-releasing hormone agonists ameliorate chronic kidney disease-induced heart failure with preserved ejection fraction.
Rieger AC; Bagno LL; Salerno A; Florea V; Rodriguez J; Rosado M; Turner D; Dulce RA; Takeuchi LM; Kanashiro-Takeuchi RM; Buchwald P; Wanschel ACBA; Balkan W; Schulman IH; Schally AV; Hare JM
Proc Natl Acad Sci U S A; 2021 Jan; 118(4):. PubMed ID: 33468654
[TBL] [Abstract][Full Text] [Related]
4. Interrelation between heart failure with preserved ejection fraction and renal impairment.
Joslin JR; Lioudaki E; Androulakis E
Rev Cardiovasc Med; 2022 Feb; 23(2):69. PubMed ID: 35229560
[TBL] [Abstract][Full Text] [Related]
5. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction.
Löfman I; Szummer K; Dahlström U; Jernberg T; Lund LH
Eur J Heart Fail; 2017 Dec; 19(12):1606-1614. PubMed ID: 28371075
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic Cell Combination Therapy Ameliorates Chronic Kidney Disease-Induced Heart Failure with Preserved Ejection Fraction.
Rieger AC; Tompkins BA; Natsumeda M; Florea V; Banerjee MN; Rodriguez J; Rosado M; Porras V; Valasaki K; Takeuchi LM; Collon K; Desai S; Bellio MA; Khan A; Kashikar ND; Landin AM; Hardin DV; Rodriguez DA; Balkan W; Hare JM; Schulman IH
Stem Cells Transl Med; 2022 Mar; 11(1):59-72. PubMed ID: 35641169
[TBL] [Abstract][Full Text] [Related]
7. Renal function, N-terminal Pro-B-Type natriuretic peptide, propeptide big-endothelin and patients with heart failure and preserved ejection fraction.
Gergei I; Krämer BK; Scharnagl H; Stojakovic T; März W
Peptides; 2019 Jan; 111():112-117. PubMed ID: 29684593
[TBL] [Abstract][Full Text] [Related]
8. Captopril Attenuates Cardiovascular and Renal Disease in a Rat Model of Heart Failure With Preserved Ejection Fraction.
Salah EM; Bastacky SI; Jackson EK; Tofovic SP
J Cardiovasc Pharmacol; 2018 Apr; 71(4):205-214. PubMed ID: 29620605
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a robust mouse model of heart failure with preserved ejection fraction.
Matsiukevich D; Kovacs A; Li T; Kokkonen-Simon K; Matkovich SJ; Oladipupo SS; Ornitz DM
Am J Physiol Heart Circ Physiol; 2023 Aug; 325(2):H203-H231. PubMed ID: 37204871
[TBL] [Abstract][Full Text] [Related]
10. Is Heart Failure with Preserved Ejection Fraction a Kidney Disorder?
Shah KS; Fang JC
Curr Hypertens Rep; 2019 Oct; 21(11):86. PubMed ID: 31599363
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Renin-angiotensin-aldosterone-system inhibitors for heart failure with preserved ejection fraction and left ventricular hypertrophy -from the KUNIUMI Registry Acute Cohort.
Odajima S; Tanaka H; Fujimoto W; Kuroda K; Yamashita S; Imanishi J; Iwasaki M; Todoroki T; Okuda M; Hayashi T; Konishi A; Shinohara M; Toh R; Hirata KI
J Cardiol; 2022 Jun; 79(6):703-710. PubMed ID: 34924235
[TBL] [Abstract][Full Text] [Related]
12. Impaired renal growth hormone JAK/STAT5 signaling in chronic kidney disease.
Wiezel D; Assadi MH; Landau D; Troib A; Kachko L; Rabkin R; Segev Y
Nephrol Dial Transplant; 2014 Apr; 29(4):791-9. PubMed ID: 24463190
[TBL] [Abstract][Full Text] [Related]
13. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.
Paulus WJ; Tschöpe C
J Am Coll Cardiol; 2013 Jul; 62(4):263-71. PubMed ID: 23684677
[TBL] [Abstract][Full Text] [Related]
14. Renal tubular damage and clinical outcome in heart failure with preserved ejection fraction and chronic kidney disease.
Otaki Y; Watanabe T; Shimizu M; Tachibana S; Sato J; Kobayashi Y; Saito Y; Aono T; Tamura H; Kato S; Nishiyama S; Takahashi H; Arimoto T; Watanabe M
ESC Heart Fail; 2023 Aug; 10(4):2458-2468. PubMed ID: 37264723
[TBL] [Abstract][Full Text] [Related]
15. Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction.
Unger ED; Dubin RF; Deo R; Daruwalla V; Friedman JL; Medina C; Beussink L; Freed BH; Shah SJ
Eur J Heart Fail; 2016 Jan; 18(1):103-12. PubMed ID: 26635076
[TBL] [Abstract][Full Text] [Related]
16. The total xanthones extracted from Gentianella acuta alleviates HFpEF by activating the IRE1α/Xbp1s pathway.
Zhao L; Qin Y; Liu Y; An L; Liu W; Zhang C; Song Q; Dai C; Zhang J; Li A
J Cell Mol Med; 2024 Jun; 28(11):e18466. PubMed ID: 38847482
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of medication therapy for patients with chronic kidney disease and heart failure with preserved ejection fraction: a systematic review and meta-analysis.
Yang L; Ye N; Bian W; Cheng H
Int Urol Nephrol; 2022 Jun; 54(6):1435-1444. PubMed ID: 34669107
[TBL] [Abstract][Full Text] [Related]
18. Renal Dysfunction and Heart Failure with Preserved Ejection Fraction.
Ananthram MG; Gottlieb SS
Heart Fail Clin; 2021 Jul; 17(3):357-367. PubMed ID: 34051968
[TBL] [Abstract][Full Text] [Related]
19. Association Between β-Blocker Use and Mortality/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease.
Fu EL; Uijl A; Dekker FW; Lund LH; Savarese G; Carrero JJ
Circ Heart Fail; 2020 Nov; 13(11):e007180. PubMed ID: 33070637
[TBL] [Abstract][Full Text] [Related]
20. microRNA-206 overexpression inhibits epithelial-mesenchymal transition and glomerulosclerosis in rats with chronic kidney disease by inhibiting JAK/STAT signaling pathway.
Zhao SQ; Shen ZC; Gao BF; Han P
J Cell Biochem; 2019 Sep; 120(9):14604-14617. PubMed ID: 31148248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
